---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-375275"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-08-31T10:01:33+00:00"
generated_at: "2026-08-31T11:01:10.528834+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin settles patent disputes with Ascendis; gets 20% US royalty on Yuviwel sales

## Summary
- Ascendis pays 20% of US net sales and 18% of EU/Brazil/South Korea net sales, retroactive to first commercial sale, until May 2030.
- BioMarin grants non-exclusive worldwide license to its CNP patents for Yuviwel (navepegritide) across all indications, incl. achondroplasia.
- All pending litigation dismissed with prejudice, including ITC Section 337 investigation and cases in Brazil, Denmark, Germany, South Korea, and N.D. Cal.
- Binding term sheet signed Aug 30, 2026; parties to finalize definitive agreement by Sept 24, 2026.

## SEC filing metadata
- accession: 0001193125-26-375275
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-08-31T10:01:33+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526375275/0001193125-26-375275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526375275/d110137d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-375275
- JSON: https://secwatch.observer/filing/0001193125-26-375275.json
- Plain text: https://secwatch.observer/filing/0001193125-26-375275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.